
Combination Venetoclax and Selinexor Effective in Relapsed Refractory Multiple Myeloma with Translocation t(11;14)

Supplementary Appendix

Table of Contents: Supplementary Figure and Text (page 2-3) Supplementary Table (page 4)

Nina Nguyen, MD^{1#}, Sana Chaudhry, BSc^{1#}, Tulasigeri M. Totiger, PhD^{1#}, Robert Diaz, MS¹, Evan Roberts, BSc¹, Skye Montoya, BSc¹, Gabriel Pardo BSc¹, Alejandro Pardo BSc¹, Jumana Afaghani, BSc¹, Maurizio Affer, MSc¹, Jacob Jahn, BSc¹, Terrence Bradley, MD³, Francesco Maura, MD², Dickran Kazandjian, MD², Daniel Bilbao, PhD¹, Jennifer Chapman, MD⁴, Ola Landgren, MD,PhD², James Hoffman, MD^{2*}, and Justin Taylor, MD^{3*}

Supplementary Figure 1



2

Supplementary Figure 1. The combination of selinexor and venetoclax show higher levels of synergy and decreased levels of Cyclin D1, XPO1, and MCL-1 protein levels in KMS12BM.

OPM2 and KMS12BM were treated with increasing doses of selinexor and venetoclax for 72 hours and cell viability was measured using CellTiter-Glo. Contour plots were calculated using the Bliss Independence model and were generated using the SynergyFinder web application. Red indicates synergism and green indicates antagonism (**Panel A and B**). The synergy of OPM2 and KMS12BM was compared using Combination Index (CI) values. The difference was measured using Student's ttest (**Panel C**). The synergy was also calculated using the CompuSyn software. Combination Index values >1 indicates antagonism, =1 indicates additivity, <1 indicates synergy (**Panel D and E**). OPM2 and KMS12BM were treated with selinexor (200nM) and venetoclax(1μM) for 16 hours and subjected to a Western blot using various antibodies as indicated (**Panel F**). The normalized protein levels of p65, p53, Cyclin D1, XPO1, and MCL-1 was calculated by the intensity of the Western blot bands using Image J software (**Panel G and H**).

Cell Lines	MM IgH translocation
U266-B1	t(11;14)(CCND1/IGH)
KMS-12-BM	t(11;14)(CCND1/IGH)
MOLP-8	t(11;14)(CCND1/IGH)
SK-MM-2	t(11;14)(CCND1/IGH)
NCI-H929	t(4;14)(MMSET/IGH)
LP-1	t(4;14)(MMSET/IGH)
OPM-2	t(4;14)(MMSET/IGH) t(?;20)(?;MAFB)
EJM	t(14;20)(IGH/MAF)
L-363	t(6;20)(?;MAFB)
KARPAS-620	t(8;11)(CCND1)
JJN-3	t(14;16)(IGH/MAF)
MM1S	t(14;16)(IGH/MAF)
KMS-11	t(4;14)(MMSET/IGH) t(14;16)(IGH/MAF)
RPMI-8226	t(16:22)(MAF;IGL)
AMO-1	-
MC-CAR	-
IM-9	-
ARH-77	-

Supplemental Table 1. List of multiple myeloma (MM) cell lines according to their immunoglobulin heavy chain (IgH) translocation.

Abbreviations: CCND1, Cyclin D1; IGH, immunoglobulin heavy chain; MMSET, multiple myeloma SET domain; IGL, immunoglobulin light chain